Cryopreservation is a key technology in medicine, biotechnology, and conservation, enabling the preservation of biological materials at ultra-low temperatures for future use. It supports medical treatments, scientific research, and species conservation by maintaining the genetic integrity of cells, tissues, and organs. Cell & Gene by Oxford Global explores its mechanisms, methodologies, applications, and the future directions this essential technology is headed towards.

How do things stand with sustainability in pharmaceutical manufacture at present? What are some members of the industry doing to reduce their carbon footprint?

The preclinical peptide could unlock much needed treatment options for patients with triple-negative breast cancer.

It is now possible to live a long and near normal life with HIV, but what is the likelihood of a permanent cure?

Microbiome-based precision oncology offers promising cancer treatment possibilities but requires clear regulations due to ethical concerns like patient safety and access. Collaboration among stakeholders is essential to balance innovation and ethics effectively.

Modulating the gut microbiome may be a key to preventing GvHD and stopping relapse.

Bioconjugate development, exemplified by ADCs such as T-DM1 and Mylotarg, tackles issues like stability and specificity, benefiting from innovative solutions and services to enhance therapeutic precision in biologics.

We discuss the challenges and safety measures in using viral vectors for gene therapies, focusing on vector selection, safety testing, quality control, and contamination prevention, highlighting their importance for the success of advanced medical treatments.

The collaboration could unlock the more cost-effective synthesis of oligonucleotide-peptide conjugates.

The CAR T therapy targets CD19 closer to the cell membrane and has demonstrated remarkable efficacy in its Phase I clinical trial.

Explore the intricate world of the immunosuppressive tumor microenvironment (TME), a key player in cancer progression and treatment resistance

Merck invests $25 million in a Kansas cell culture media plant, aiming to meet rising demand for advanced therapeutics while aligning with sustainability goals.